Document is current
Any future updates will be listed below
-
Authors
Lathuiliere, Aurelien
Jo, Youhwa
Perbet, Romain
Donahue, Cameron
Commins, Caitlin
Quittot, Noé
Fan, Zhanyun
Bennett, Rachel E.
Hyman, Bradley T. https://orcid.org/0000-0002-7959-9401
-
Funding
Funding for this research was provided by:
AbbVie
Rainwater Charitable Foundation
National Institute of Health (R56AG061196, RF1AG059789, RF1AG058674, P30AG062421)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ELP3_184403)
Alzheimer's Association (AACSF-19-617308)
Stiftung Professor Dr. Max Cloëtta
H2020 Marie Skłodowska-Curie Actions (839098)
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 28 July 2023
First Online: 8 August 2023
Declarations
:
: Human tissue was provided by the Massachusetts Alzheimer’s Disease Research Center (ADRC) with approval from the Mass General Brigham IRB (1999P009556).
: Not applicable.
: Dr Hyman has a family member who works at Novartis, and owns stock in Novartis; he serves on the SAB of Dewpoint and owns stock. He serves on a scientific advisory board or is a consultant for AbbVie, Aprinoia Therapeutics, Arvinas, Avrobio, Axial, Biogen, BMS, Cure Alz Fund, Cell Signaling, Eisai, Genentech, Ionis, Latus, Novartis, Sangamo, Sanofi, Seer, Takeda, the US Dept of Justice, Vigil, Voyager. His laboratory is supported by research grants from the National Institutes of Health, Cure Alzheimer’s Fund, Tau Consortium, and the JPB Foundation – and sponsored research agreements from Abbvie, BMS, and Biogen.
